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A receptor for fluid phase human complement (C) components C3 and C3b (1, 
2) was found on the surface membranes of human lymphoblastoid cells. No other 
C proteins or serum factors were needed to mediate binding of C3 or C3b to this 
receptor. In studying its biological importance, we demonstrated that Raji cells 
cultured in medium containing fresh normal human  serum (NHS) 1 and cobra 
venom factor (CoF) were lysed (1). Results were similar when C3b-bearing Raji 
cells were cultured in medium with fresh NHS. In other experiments, lysis was 
eliminated by inactivating  serum factor B. 2 Therefore,  we concluded that C3b 
bound  to  the  Raji  cells  activated  the  C  system  through  C3b-dependent  C3 
convertase (3, 4) which resulted in fixation of the later C components directly on 
the cell membranes, thereby leading to their damage and lysis. 
Joseph et al. (5) observed that immune human serum, containing antimeasles 
virus antibody and C, lysed HeLa cells infected with measles virus via activa- 
tion of the alternative C pathway (6). By using immunofluorescence, properdin 
(P) was detected on the surfaces of the measles virus-infected HeLa cells previ- 
ously incubated with the immune  serum (Perrin,  L.,  and M.  B. A.  Oldstone, 
unpublished  observations).  Therefore we questioned,  do components of the P 
system bind to cells,  and if so, what events lead to their fixation on the cell 
surface? We now show that P, as well as factor B, can bind to surfaces of certain 
lymphoblastoid cells and of human B type peripheral lymphocytes. The fixation 
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immune adherence negative EA coated with C1-C3 from mouse serum deficient in C5; EAC3b  ra~, 
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of P  and  factor  B  on  cells  is  mediated  by  binding  of C3  or  C3b  to  C3-C3b 
receptors. Furthermore, binding of P precedes that of factor B or stabilizes the 
binding of factor B to C3b. 
Materials and Methods 
Lymphoblastoid  Cell Lines.  The origins of the Raji, Daudi,  Wil2WT, 8866,  Sommer 8402  (2), 
P3HR1 (7), and MOLT-4 (8) cell lines have been described. These cell lines were cultured in Eagle's 
minimum essential medium  (MEM; Autopow; Flow Laboratories,  Inc.,  Rockville,  Md.) supple- 
mented with glutamine, nonessential amino acids, pyruvate, 10% fetal bovine serum, penicillin, 
streptomycin, and fungizone (1). 
Purified Proteins  and C Reagents.  Human  C3  and  C3b  [1  mg/ml  Veronal-buffered saline 
containing 1.5 ×  10  -4 M CaC12 and 5 ×  10 -4 M MgC12 (VBS)] were prepared as published (9, 10) and 
were a gift from Dr. V. A. Bokisch (Scripps Clinic and Research Foundation, La Jolla, Calif.). Of 
two preparations of P,  the first was purified as described (11),  and the second was purified by 
affinity chromatography with rabbit antiserum to  human P  coupled  to  Sepharose 4B  (12,  13) 
(Pharmacia Fine Chemicals, Inc., Uppsala Sweden). A euglobulin pool made 0.01 M with EDTA 
(ethylenediaminetetraacetate) was used as the source of P. After prolonged washing with NaC10.5 
M, EDTA 0.01 M, pH 7.2, P was eluted with potassium thiocyanate 2 M, pH 6.5; the eluted fraction 
was immediately dialyzed against VBS. Both preparations were adjusted to 200 ~g P/ml VBS. P 
prepared  by the first method was free of contaminating proteins when tested by Ouchterlony 
analysis and immunoelectrophoresis with antiwhole human serum, antihuman C3, C4, C5, and 
factor B, and migrated cathodally when reacted with rabbit antiserum to human P in immunoelec- 
trophoresis. The second preparation of P presented the same characteristics, but a trace amount of 
IgG was detected by Ouchterlony analysis. Results obtained with both preparations were invaria- 
bly the same.  Factor B  was purified either as published (6) or by affinity chromatography with 
rabbit antiserum to human factor B coupled to Sepharose 4B (14) as above. The isolated factor B 
preparations were concentrated to 500 ~g/ml VBS. Both preparations were free of contaminating 
proteins as determined by Ouchterlony analysis and immunoelectrophoresis and behaved simi- 
larly in the experiments reported below. Factor D was partially purified by concentrating to one- 
fifth of their original volume the fractions containing factor D activity which were recovered after 
the exclusion peak of NHS filtered through a  Sephadex G75 column.  Factor D  activity in the 
fractions was checked  by a  hemolytic radial  immunediffusion method. 3 Briefly,  we used 0.6% 
agarose plates containing a final concentration of 5 mM Mg  +÷, 10 mM EGTA, the exclusion peak of 
a  NHS  pool  filtered through a  Sephadex  G75 column (15)  diluted  1/20,  and 0.75%  guinea pig 
erythrocytes. The fractions were applied in the wells, and the plates were incubated first at 4°C for 
24 h and then at 37°C for 3 h before reading the hemolytic rings. Human sera, our source of C, were 
obtained from the blood of healthy laboratory personnel, clotted for 60 min at room temperature 
and then 30 min at 4°C,  and subsequently centrifuged. Sera were used immediately or frozen at 
- 70°C. Human serum genetically deficient in C2 was provided by Dr. C. Arroyave (Scripps Clinic). 
Aged human serum was obtained by incubating NHS for 10 days at 4°C.  NHS made 0.01 M with 
respect to EDTA and adjusted to pH 7.5 by NaOH 0.1 N was selectively depleted of P by passage 
through a column of Sepharose 4B coupled to rabbit antiserum to human P. The serum was then 
concentrated by negative pressure to the original volume and dialyzed against VBS. Similarly, 
rabbit  antiserum  to  human  factor  B  coupled  to  Sepharose  4B  was  used  to  obtain  a  serum 
selectively depleted of factor B. The exclusion peak of NHS made 0.01 M with respect to EDTA, 
after filtration through a  Sephadex G75, was concentrated by negative pressure to the original 
volume and dialyzed against VBS; this preparation was used as factor D-depleted serum (15, 16). 
Human serum was depleted of C3 as described by Lachmann by incubating two parts of purified 
F(ab')2 goat antihuman C3 with one part of NHS in the presence of 0.01 M  EDTA (17).  The C3- 
depleted serum was dialyzed against VBS before use. The P, factor B, and factor D depleted sera 
each had a CHs0 greater than 60 U (normal values +_ 2 SD:65-100) and did not convert C3 or factor 
3 Martin, A., P. J. Lachman, L. Halbwachs, and M. J. Hobart. 1976. Haemolytic diffusion plate 
assays for factors B  and D  of the alternative pathway of complement activation. Submitted for 
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B after incubation with inulin (20 mg/ml final concentration). Each activity was restored by the 
respective addition of each purified,  depleted component.  Human IgA was  a  gift from  Dr.  H. 
Spiegelberg (Scripps Clinic). Human IgG was prepared as described (2). Human IgA and IgG were 
aggregated  in samples heated at 63°C  for  10 min and 30 min,  respectively.  EDTA  and EGTA 
[ethyleneglycolbis (B-amino-ethylether) N, Nl-tetraacetic acid] were purchased from Sigma Chem- 
ical Co., St.  Louis, Mo. 
Activators of the Alternative C Pathway.  Inulin was purchased from Pfanstiehl Labs.,  Inc., 
Waukegan, Ill., zymosan from Nutritional Biochemicals Corporation, Cleveland, Ohio, endotoxin 
from S.  marcescens  from Difco Laboratories, Detroit,  Mich., and CoF containing 100 U/ml VBS 
from Cordis Laboratories Miami, Fla. 
Activation of C in NHS.  An appropriate amount of zymosan or inulin was washed twice with 
VBS. After centrifugation at 2,000 g  for 10 min at 22°C,  the supernate was removed. Prewarmed 
NHS (37°C) was added to 2 mg of the zymosan pellet/ml or 20 mg of the inulin pellet/ml serum, and 
the mixture was agitated. After incubation for 30 min at 37°C with periodic shaking (every 5 min), 
the serum was separated from the zymosan or inulin particles by centrifugation (2,000 g, 4°C, 15 
min) and used immediately to appraise the effect of these activators on the binding of P and factor 
B to cells. NHS was also incubated for 30 min at 37°C with CoF (100 U/ml), endotoxin (1 mg/ml), 
isolated human C3b (1 mg/ml), aggregated human IgA (3 mg/ml), or aggregated human IgG (AHG; 
5 mg/ml), and after centrifugation at 4°C for 15 min was used immediately for binding studies. 
Antisera.  Monospecific antisera (1) to human C3 were raised in rabbits and goats (10).  Fab'2 
goat anti-C3 was prepared by pepsin digestion of human C3-goat antihuman C3 complexes (17). 
Antisera to human P  and to human factor B  were raised in rabbits by injecting 50 and 200  ~g, 
respectively,  of the  isolated proteins  with  incomplete  Freund's  adjuvant  three  times  at  2-wk 
intervals. These antisera had one precipitation line when reacted  with the isolated respective 
proteins and whole  NHS.  Antisera to Bb and Ba fragments of human factor B  were raised in 
rabbits (16). Rabbit antiserum to human immunoglobulins (IgG + IgA + IgM) was purchased from 
Cappel  Laboratories,  Downington,  Pa.  Antiserum to rabbit IgG was raised  in sheep.  The IgG 
fraction of these antisera was obtained by fractionation on a  DEAE-52  cellulose  column after 
elution with 0.015 M phosphate buffer, pH 7.2, and subsequently was conjugated with fluorescein 
isothiocyanate (FITC) by dialysis (18).  The FITC-conjugated antisera were dialyzed versus phos- 
phate-buffered saline (PBS) and used at a concentration of 10 mg/ml PBS. 
Immunofluorescence.  For the detection of cell bound C3 or C3b and P, direct immunofluores- 
cence was used.  5  x  l0  s cells (washed three times with MEM or physiologic saline) in 25 ~l of 
MEM, saline, or VBS and with various amounts of isolated human C components, NHS,  human 
serum  with  activated  C,  or  serum  depleted  of certain  C  proteins  were  incubated with gentle 
agitation at 37°C for 30 min. Subsequently, cells were washed three times with MEM and agitated 
during incubation for 30 min at 4°C with 25 ~1 of the FITC antiserum to C3 or to P. 
Cell bound factor B was detected with indirect immunofluorescence. Cells were first incubated 
(30 min, 37°C) with various amounts of isolated factor B, NHS, human serum depleted of certain C 
proteins,  or  human serum  which had  first  reacted  with different  activators of the  C  system. 
Subsequently, cells were washed as above and reacted (30 min, 4°C) with 25 ~l of FITC antifactor 
B. The cells were then washed three times with MEM and incubated (30 min, 4°C) with 25 ~1 of a 
nonfluorescein-conjugated  sheep  antirabbit IgG  (5  mg/ml)  in  order  to  cross-link molecules  of 
antifactor B bound to cells. Finally in both direct and indirect techniques, cells were washed three 
times with MEM and resuspended in 10 ~1 of a  10% bovine serum albumin (BSA) in saline. Cell 
smears were prepared and observed as described (1). Since all cells in a given preparation stained 
to the same degree, we could semiquantitatively classify the intensity of stain from negative to 4 + 
for both P  and factor B binding. 
Erythrocyte-Antibody-Complement  Complexes  (EAC).  EAC3b  rabbit  cells  (EAC3b  tab)  and 
EAC3d mouse cells (EAC3d m°) were prepared from sheep erythrocytes (E) sensitized with rabbit 
antierythrocyte antibody (A) and incubated with rabbit serum genetically-deficient in C6 (19) or 
mouse serum genetically-deficient in C5 (20), respectively (2). EAC3b  tab cells (immune adherence 
positive) and EAC3d m° cells (immune adherence negative) (2) were used in a rosette assay (1, 2) to 
demonstrate C3b and C3d receptors on cells. Receptors for C3b on human lymphoblastoid cell lines 
were  also  sought by using soluble human  C3  or  C3b  in the  direct immunofluorescence assay 
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or closely associated (1). The presence of receptors for C3-C3b and C3d on human lymphoblasteid 
cell lines studied here, except the MOLT-4 and P3HR1 lines, was established previously (2) and is 
compared with the ability of these cells to fix P  and factor B. 
Rosette  Formation  of  Lymphoblastoid  Cells  with  Zymosan-Complement  Com- 
plexes.  Preparation of zymosan-C complexes (ZC) and detection of ZC rosette-forming lympho- 
btastoid cells were performed exactly as described by Mendes et al.  (21). 
Human Peripheral Lymphocytes (HPL).  HPL from healthy persons were isolated by defibrina- 
tion, dextran sedimentation, and Ficoll-Isopaque centrifugation (1). Monocytes were removed with 
a lymphocyte-separating reagent (Technicon Instrument Corp., Tarrytown, N. Y.) and a magnet 
(22) and then were washed three times and suspended in MEM. 97-99% of the cells obtained were 
lymphocytes. We removed  C receptor-bearing  cells  by  incubating samples  of  2 x 106  HPL in  200  ~I 
MEM  for 30 rain  at 37°C with 25 pl of  EAC3b  ~b. Subsequently, 20 such samples were mixed 
carefully,  layered over 2 ml of  Ficoll-lsopaque,  and centrifuged  for  15 min at 1,000  g. C receptor- 
bearing HPL (rosetting)  were  found  at  the bottom  and  non-C receptor-bearing  cells  (nonrosetting) 
at  the interface. 
Immunoeleetrophoresis. 50-200 pl of NHS  were incubated alone or with 5 ×  10  ~ cells  of 
different  cell  lines  with  gentle  shaking  for  30  min  at  37°C.  After  centrifugation  (1,000g)  for  10  min, 
the supernates were made 0.01  M  with  respect  to  EDTA before  being  imrnunoelectrephoresed. C3 
and  factor  B were  immunoelectrophoresed  in  1.5%  agar  in  diethylbarbiturate  buffer  0.1M, 0.005  M 
EDTA, pH 8.2,  as was P in 1% agarose and the same buffer  as above. 
Trypsin Treatment.  5 ×  106 cells were incubated with 0.01% trypsin in MEM alone for 15 min 
at 37°C and then washed twice with 0.1% soy bean trypsin inhibitor in MEM containing 10% fetal 
bovine serum. 
Results 
Binding of P to Raji Cells.  When Raji cells were incubated in 25 ~1 MEM, 
saline,  or VBS containing  100 Izl of fresh NHS, nearly 100% of the cells were 
positive when subsequently stained with FITC anti-P (Fig. 1). Control Raji cells 
incubated  with  MEM  only  and  stained  were  negative.  The  antiserum  was 
specific since  no  staining  occurred  with  cells  incubated  with  NHS  and  then 
reacted with FITC anti-P previously absorbed with isolated P. In addition, cells 
incubated  with  NHS and then  reacted with FITC  anti-P previously absorbed 
with washed ZC particles did not stain.  Furthermore,  cells incubated with 200 
of other proteins, such as C3, C3b, and 7S IgG, known to bind to Raji cells (1, 
2), and reacted with FITC anti-P remained negative.  Raji cells incubated with 
C2-deficient human serum and stained with FITC anti-P were immunofluores- 
cence positive. In contrast, cells were negative when reacted with FITC anti-P 
after incubation with either (a) 50 ~g of isolated P, (b) 100 Izl aged human serum 
which contained cathodically migrating P (23), C3d, and C3c, but not C3 and C3b 
(24),  or (c) heated (56°C,  30 min)  serum.  Fixation of P  to cells was somewhat 
temperature  dependent.  Incubation with NHS at 4°C for 30 min gave weakly 
positive reactions;  whereas  incubation  at  37°C  for  30 min  yielded maximum 
intensities of immunofluorescence. 
The binding of P to cells, as graded by intensity of immunofluorescence, was 
enhanced after incubation of cells with human serum first reacted with inulin, 
endotoxin, or aggregated IgA (Table I). AHG did not appreciably increase the 
intensity of staining over that of NHS alone. Cells incubated with serum first 
reacted  with  zymosan  (2 mg/ml)  and  subsequently stained  with  FITC  anti-P 
showed  very  weak  or  no  staining.  EDTA  (10  mM)  added  to  serum  before 
incubation with the cells or trypsin pretreatment of cells precluded binding of P. 
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FIo.  1.  P bound to Raji cells seen by immunofluorescence. Cells were incubated with NHS 
at 37°C for 30 min and then stained with FITC anti-P (4°C, 30 min). Magnification x 630. 
Raji cells as judged by immunofluorescence.  Finally,  EDTA added to a  serum 
already activated by inulin did not inhibit fixation of P  to cells. 
Immunoelectrophoretic analysis of NHS incubated at 37°C for 30 min without 
cells showed slow cathodally migrating P. In contrast, fast cathodally migrating 
P  was detected in the supernate  of 100 ~  of the same serum after incubation 
with 5 ×  10  ~ Raji cells at 37°C for 30 min (Fig. 2 ). When 5  ×  10  ~ Raji cells were 
incubated (37°C, 30 min) with 50/zl of NHS, and the supernate was analyzed by 
immunoelectrophoresis,  no  P  was  found,  indicating  that  all  of the  P  in  this 
amount of serum had been adsorbed to the cells. 
Binding of  Factor B to Raft Cells.  When Raji cells were incubated in MEM, 
saline, or VBS containing 100 ]zl of fresh NHS or up to 250 pg of isolated factor 
B, then stained with FITC antifacter B, no cells immunofluorescence positive for 
factor B were observed. In contrast, incubation of  cells with either 100/zl NHS or 
C2-deficient serum first treated with inulin resulted in nearly 100% immunofluo- 
rescence positive cells (Fig. 3). Neither incubation of cells with 100 ~l of heated 
(50°C, 30 min) human serum nor with serum specifically depleted of C3, P, factor 
B, and factor D, but treated with inulin,  resulted in factor B fixation to cells. 276  PROPERDIN  AND  FACTOR  B  BINDING  TO  LYMPHOID  CELLS 
TABLE  I 
Effect of Activators  of the P System on the Binding of P to Raji 
Cells * 
Intensity$ of immunofluores-  Incubation  eence 
NHS  1+ 
NHS +  inulin  4+ 
NHS +  endotoxin  2+ 
NHS +  zymosan  _+  to negative 
NHS  +  aggregated IgA  2+ 
*Raji cells were incubated with NHS or NHS first treated with the 
activators. Subsequently, the washed cells were stained with FITC 
anti-P. 
Graded from negative to 4+. 
FIG. 2.  Conversion of  P after  incubation of  NHS  with Raji  cells.  (a)  The upper well con- 
tains  NHS  incubated at  37°C for  30  rain  without  cells.  (b)  The lower  well  contains  the  super- 
nate  of  the  same NHS  after  incubation (37°C,  30  rain)  with  cells.  Trough was  filled  with  rab- 
bit  antihuman P.  The slide  was stained  with amido  black.  Cathode was  on  the  left.  Note the 
cathodal shift  of  the P arc in (b). 
However, when physiologic amounts of the respective proteins were added to the 
depleted sera and incubated with inulin,  factor B bound to cells. Factor B fixed 
to  Raji  cells  with  inulin-treated  NHS  and  also  with  serum  pretreated  with 
zymosan,  endotoxin,  isolated  human  C3b,  CoF,  aggregated  IgA,  and  AHG 
(Table II). The binding of factor B to cells was temperature dependent resulting 
in weak staining  after incubation  at 4°C  with inulin-activated  human  serum 
and strong staining after incubation at 37°C. When Raji cells carrying factor B 
(after interaction  with  inulin-treated  NHS) were  stained with  FITC  antisera 
reacting preferentially with the Bb or the Ba fragments of factor B, immunoflu- 
orescent staining  was intense with the former but very weak with the latter. 
The addition of 10 mM EDTA,  but not EGTA,  to NHS before incubation with 
inulin prevented binding of factor B to cells. However, when EDTA was added to 
serum already activated by inulin, fixation of factor B proceeded normally. Raji 
cells pretreated with trypsin could not fix factor B from inulin-treated  human 
serum. 
Immunoelectrophoretic  analysis of the supernate  obtained after incubating 
(30 min, 37°C) NHS (not treated with inulin) with Raji cells revealed conversion 
of factor B (Fig. 4). Control NHS incubated as above, but without cells, did not 
convert factor B. 
Sequence  of Events  Leading  to  the  Binding  of P  and  Factor  B  to  Raji 
Cells.  Since P  and factor B bound to Raji cells only in the presence of other A.  N.  THEOFILOPOULOS  AND  L.  H.  PERRIN  277 
FIG.  3.  Factor B bound to Raji cells shown by immunofluorescence. Cells were incubated 
with NHS which first had reacted with inulin. Subsequently, the washed cells were stained 
with FITC antifacter B and then reacted with sheep antirabbit IgG without FITC. Magnifi- 
cation x  630. 
serum  factors,  it  was  important  to  identify  these  factors,  their  sequence  of 
binding, and their structural element(s) which mediates this binding. As shown 
in Tables III and  IV:  (a)  Raji cells incubated with C3-depleted human  serum 
then reacted with FITC anti-P showed no immunofluorescence positivity. Other 
Raji cells incubated with C3-depleted serum first treated with CoF, then stained 
with FITC  antifactor  B,  also were negative.  Activation  of factor B  by CoF is 
known to be independent of the presence of C3 (4,  25).  (b) One sample of Raji 
cells was incubated with a  mixture of C3 or C3b and P  and another was first 
reacted with C3 or C3b, washed three times with MEM, and then incubated with 
P.  When  both  samples  were  stained  with  FITC  anti-P,  immunofluorescence 
appeared.  Control  cells  similarly  incubated  with  P  alone  and  stained  were 
negative. (c) C3b-bearing Raji cells were reacted with anti-C3 and then with P; 
no immunofluorescence-positive cells were observed after staining  with FITC 
anti-P.  (d) Raji cells were incubated with factor B or factor D-depleted serum, 
washed three  times with  MEM,  and  then  stained  with FITC  anti-P.  Almost 278  PROPERDIN  AND  FACTOR  B  BINDING  TO  LYMPHOID  CELLS 
TABLE II 
Effect of  Activators of the P System on the Binding of  Factor B to 
Raft Cells* 
Incubation  Intensity of immunofluores- 
cense$ 
NHS  Negative 
NHS + inulin  4+ 
NHS + zymosan  3+ 
NHS + endotoxin  1+ 
NHS + C3b  1+ 
NHS + CoF  1  + 
NHS + aggregated IgA  1+ 
NHS + AHG  1+ 
* Raji cells were incubated with NHS or NHS first treated with the 
activators.  Subsequently,  the washed cells were incubated with FITC 
rabbit antifactor B and nonfiuorescein-conjugated  sheep  antirabbit 
IgG. 
$ Graded from negative to 4+. 
Fla.  4.  Immunoelectrophoretic demonstration of  Raji cell-induced  conversion of  factor  B 
in  NHS: (a)  The upper  well  contains NHS incubated at  37°C for  30  rain  without  cells.  (b)  The 
lower well contains the supernate  of  the same NHS  after  incubation (37°C,  30 rain)  with 
cells.  Trough was filled  with rabbit  antihuman factor  B. The slide  was stained with amido 
black.  The cathode was  on  the  right.  Note  the  appearance of  a  second  arc  in  (b)  representing 
the Bb fragment of  factor  B. 
100%  of cells were immunofluorescence positive.  (e)  Raji  cells were first  incu- 
bated with  C3b,  washed,  and then  reacted with  NHS.  After the washed cells 
were stained  with FITC antifactor  B,  nearly all were weakly immunofluores- 
cence positive. (f) Raji cells were incubated with a  mixture of C3b, factor D, and 
factor B or they were first reacted with C3b, washed, and then incubated with a 
mixture  of factor  D  and  factor  B.  When  the  washed  cells were  subsequently 
stained with FITC antifactor B, no cells were immunofluorescence positive.  (g) 
samples of cells  were  incubated  with  mixtures  of C3b  and  P-depleted  serum 
with or without isolated P. Activation of factor B by C3b is independent of P  (15). 
When these cells were stained with FITC antifactor B, the former cells, but not 
the  latter,  were  immunofluorescence positive.  In summary,  binding  of P  and 
factor B  to cells evidently requires the presence of C3 or C3b, and binding of P 
seems to be necessary for the fixation or stabilization of cell-bound factor B. 
Additional experiments were performed to demonstrate that binding of P  and 
factor B to cells follows fixation of C3 or C3b to C3-C3b receptors. Several human 
lymphoblastoid cells lines were checked for C3-C3b receptors and binding of P A.  N.  THEOFILOPOULO8  AND  L.  H.  PERRIN  279 
TABLE  III 
Fixation of P  to Raft Cells via C3-C3b Receptors and Independence of P Binding from 
Factor D and Factor B* 
Cell type  First incubation  Second incubation  Third incubation 
Immuno- 
fluores- 
cence posi- 
tive cells 
Raji  C3  FITC anti-C3  --  100 
"  C3b  "  --  98 
"  NHS  "  --  100 
"  NHS  FITC anti-P  --  100 
"  HS~-depleted of C3  "  --  0 
"  P  "  --  0 
"  C3  +  P  "  --  90 
"  C3b  +  P  "  --  92 
Raji+  C3  P  "  --  100 
Raji + C3b  P  "  --  95 
Raji + C3b  Rab-anti-C3  P  FITC anti-P  0 
Raji  HS-depleted of P  FITC anti-P  --  0 
"  HS-depleted of factor D  "  --  92 
"  HS-depleted of factor B  "  --  97 
* 50  ~g  of  C3  or  C3b,  10~g  of  P,  and  100  ~l  of NHS  or  human  serum  depleted of  certain 
proteins were employed. 
HS, human  serum. 
TABLE  IV 
Fixation of Factor B  to Raji Cells via C3-C3b Receptors and 
Dependence or Stabilization of Its Fixation by P* 
Cell type  Incubation 
Immunofluo- 
rescence posi- 
tive cells$ 
% 
Raji  NHS  0 
"  NHS  +  CoF  95 
"  HS-depleted of C3  +  CoF  0 
"  C3b  +  NHS  89 
Raji +  C3b  NHS  93 
Raji  C3b  +  factor D  +  factor B  5 
Raji ÷  C3b  factor D  +  factor B  2 
Raji  C3b +  HS-depleted of P  5 
Raji  C3b  +  HS-depleted of P  +  P  95 
* 50 I~g of C3b, 50 ~1 of facter D, 50/J4g of factor B, 10 ~g of P, and 100 p~l 
of NHS or human  serum (HS)  depleted of certain proteins were em- 
ployed. 
Cells were stained with FITC rabbit antifactor B  and then incubated 
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TABLE  V 
Relationship  of Receptors for C3-C3b and C3d to Fixation of P and Factor 
B on Human Lymphoblastoid Cell Lines 
Cell type 
Percent cells forming  Percent cells  rosettes with:  binding* C3 or 
C3b 
Percent cells bindingS: 
EAC3b  r~'  EAC3d  m°  P  Factor B 
Raji  100  96  98  100  100 
Daudi  90  2  35  92  90 
Wil2WT  2-3  1  0  0  0 
8866  5  3  0  0  0 
P3HR-1  0  0  0  0  0 
MOLT-4  0  0  31  0  0 
Sommer 8402  0  0  53  0  0 
* The binding of soluble C3 or C3b was assessed by staining with FITC anti-C3. 
S The binding of P and factor B was assessed by incubating the cells with NHS which 
had first reacted with inulin and by subsequent staining with FITC anti-P in the 
former and FITC rab-antifactor B and sheep antirabbit IgG in the latter. 
and factor B. The results in Table V  indicate an absolute correlation between 
the presence of receptors for C3-C3b and the ability of cells to fix P  and factor B. 
MOLT-4 and Sommer 8402 cells which have C3d, but not C3-C3b receptors, were 
unable to bind P  and factor B. Immunoelectrophoretic studies of the supernate 
obtained  from incubating  NHS  with  all  cell  lines  studied,  as  done  with  Raji 
cells, revealed activation of P  and factor B. 
We (unpublished  observations) and others (21)  have observed that ZC parti- 
cles incubated  with  lymphocytes bearing C  receptors adhere to cells and form 
rosettes (Fig. 5). Surfaces of ZC particles carry fragments of C3, P, and factor B 
(26-29).  However, preincubation  of washed ZC with  an  antihuman  C3  serum 
completely inhibited their adherence to Raji cells (Table VI). In contrast, treat- 
ment of ZC with anti-P or antifactor B had no effect on the adherence of ZC and 
rosette formation with Raji cells. Furthermore, addition of 200 p~g of C3b to Raji- 
ZC rosettes dissociated the rosettes. Finally, preincubation of Raji cells with 100 
~g C3b  inhibited  the  adherence  of ZC  to cells (Table  VI).  These experiments 
showed conclusively that binding of P  and factor B to cells was not mediated by 
specific cellular receptors for these proteins. 
Binding of P  and factor B  to HPL.  Inasmuch as some human lymphoblas- 
toid cell lines bound P  and factor B, we investigated whether HPL also bound 
these proteins (Table VII). HPL stained directly after the purification steps did 
not carry P  or factor B.  Furthermore,  in contrast to lymphoblasts,  HPL incu- 
bated with NHS did not bind P. However, incubating HPL with NHS pretreated 
with  inulin  and  staining  with  FITC  anti-P  or  FITC  antifactor  B  resulted  in 
approximately 20-25% immunofluorescence-positive cells. Next HPL were incu- 
bated  with  EAC3b tab, then  nonrosetting  cells  obtained  at  the  interface  after 
Ficoll-Isopaque gradient  centrifugation  were  reacted  with  human  serum  pre- 
treated with inulin and stained with FITC anti-P or FITC factor B, after which 
no immunofluorescence-positive cells were observed. In contrast, the majority of 
rosetted cells bearing  C  receptors  (after  lysis of the  attached  erythrocytes by A.  N.  THEOFILOPOULOS  AND  L.  H.  PERRIN  281 
Fro.  5.  Rosette  formation  between  Raji cells and ZC. (a) Magnification  ×  250. (b) Magnifi- 
cation  ×  630. 
TABLE  VI 
Adherence of  ZC Particles Carrying C3b, P, and Factor B to Raji 
Cells by C3-C3b Receptors 
Cell type  First  incubation 
S 
,.  1  Percent  ro- 
econa lncuoa-  _  . 
tion  sette-ibrmmg 
ceils 
Raji  ZC  MEM  100 
"  ZC-anti-C3  "  0 
"  ZC-anti-P  '~  98 
"  ZC-anti-factor  B  "  100 
"  ZC  C3b  5 
Raji  +  C3b  ZC  MEM  3 
brief exposure to 0.17 M  NH4C1)  incubated with NHS activated by inulin  and 
subsequently stained possessed both P  and factor B (Table VIII). These results 
show that HPL carrying C3b receptors, and which are considered of B type (30), 
are the cells that bind P  and factor B. 
Discussion 
The present  studies demonstrate  that  under  appropriate  conditions  certain 
human lymphoblastoid cells as well as HPL of the B type bind P  and factor B. 
Furthermore,  fixation of these proteins to cells follows binding of C3 or C3b to 
C3-C3b receptors. 
Immunoelectrophoretic  studies of the supernate  from incubating  NHS with 
lymphoblastoid cells revealed  activation  of P  and  factor  B.  Furthermore,  re- 282  PROPERDIN  AND  FACTOR  B  BINDING  TO  LYMPHOID  CELLS 
TABLE  VII 
Binding of P and Factor B  to HPL 
Incubation  Staining procedure 
Immunofluo- 
rescence posi- 
tive cells 
% 
MEM  FITC anti-P  0 
NHS  "  0 
NHS +  inulin  "  19 
MEM  FITC rab anti-factor B-sheep  0 
anti-rab IgG 
NHS  "  0 
NHS  +  inulin  "  25 
TABLE  VIII 
Percentage of Unseparated HPL and Ficoll-lsopaque Separated 
EAC3b ra~ Rosetted and Nonrosetted Cells which Bind P and 
Factor B 
Percent  Percent cells binding* 
EAC3b  ra~) ro- 
setting cells  P  Factor B 
Unseparated HPL  19  20  24 
Interface  0  1  3 
Pellet  58  52  61 
* The binding of P  and factor B  was assessed by incubating the cells 
with NHS that had first reacted with inulin and by subsequent stain- 
ing with FITC  anti-P in the former and FITC  rab-antifactor B  and 
sheep antirabbit IgG in the latter. 
moval of Ca  ++ and Mg  +÷ by EDTA, but not removal of Ca  ÷+ alone with EGTA, 
from NHS inhibited fixation of P  to Raji cells.  Thus,  human lymphoblastoid 
cells, like other particulate materials such as zymosan and inulin (26-29, 31, 32), 
can activate the P system. Since no P was detected by immunoelectrophoresis in 
the  supernate  obtained  after  incubation of 5  x  106  cells  with  50  t~l  NHS, 
apparently about 2  x  105 molecules of P  bound per Raji cell. The reason why 
lymphoblasteid cells in continuous culture activate the P  system is not appar- 
ent. Possibly these cells are endowed with P  system-activating enzymes or C- 
activating factors. Such factors have been found in supernates of HPL stimu- 
lated with mitogens (33). The possibility that endotoxin, a  known activator of 
the P system (34), was present in the milieu cannot be excluded. Alternatively, 
the surfaces of these cells may carry virus or viral proteins capable of activating 
the C system. Others have found that virus-transformed murine lymphocytes  fix 
C1  from serum  (35), and  that  polyoma virus,  Moloney virus,  and  vesicular 
stematitis virus activate C in the absence of antibody (36, 37). 
The enhanced binding of P to cells, as judged by the intensity of immunofluo- 
rescence after using inulin, endotoxin, or aggregated IgA-treated human serum, 
agrees with the previously shown activation of  the P system by these substances A.  N.  THEOFILOPOULOS  AND  L.  H.  PERRIN  283 
(31, 32, 34, 38, and footnote 4). Furthermore, this finding may indicate that the 
cells by themselves are not as potent activators of  P or other serum factors, such 
as C3, potentiating the fixation of P to cells as the above substances. AHG could 
not enhance P binding just as AHGs were previously shown to be ineffective in 
triggering the P system  4. Diminution of P fixation after incubation of cells with 
human serum pretreated with zymosan, under conditions which did not result in 
substantial  removal  of C3,  indicated  that  most  of the  P  adhered  to  these 
particles. Concentrations of zymosan similar to or smaller than those used in 
this study are known to remove the P from serum (32). 
The presence of P  on cells incubated with NHS or human serum with acti- 
vated C  and the absence of P  on cells incubated with isolated P, aged human 
serum, and C3-depleted serum indicated that C3 or C3b were necessary for the 
binding of P to cells. This conclusion was reinforced by the fact that isolated P 
added with isolated C3 or C3b or added alone to Raji cells with bound C3 or C3b 
could fix to the Raji cells. Furthermore, cell lines devoid of C3-C3b receptors did 
not bind P. Recent studies have suggested that P in serum is a 6S molecule that 
forms weak  complexes  with  native  or  altered  C3  and  possibly other  serum 
factors, such as factor D and factor B (39). Fearon and Austen (40, 41), as well as 
Schreiber et al. (42), demonstrated that P binds to EAC43b, but not to EAC4, 
and that P bound to EAC43b does not decay significantly  from the intermediate 
during 30-min incubation at 37°C. Fixation of P  to Raji cells, as shown in the 
present study, was independent of factor B and factor D. 
In contrast to the binding of  P, factor B could not be demonstrated on Raji cells 
interacted with NHS or C2-deficient serum. However, factor B did bind after 
incubation of  cells with serum first reacted with inulin or other activators of the 
P system. The reason why factor B activated by Raji cells, in constrast to factor 
B activated by inulin or the other activators, did not fix to the cells is not clear. 
Activators other than cells may generate more activated factor B  and other 
serum factors needed for fixation or stabilization, such as C3b and activated P, 
than cells produce. Fearon et al. demonstrated that factor B decayed rapidly and 
was released into the milieu after EAC43b carrying factor D and factor B were 
incubated at 37°C. The half-life of the EAC43 bound convertase was only 4-6 
min at 30°C (40, 41, 43). Brade et al. (26-28)  found similar decay of factor B on 
zymosan particles and failure of factor B released from the particles to rebind. 
Conceivably then, the inability to detect factor B on cells incubated with NHS 
may be due to the decay and release of the bound factor B. Alternatively, as 
stated above, it may be that cells, in contrast to other activators, do not generate 
C3b and, therefore, factor B cannot bind to cells. In the case of  P such generation 
of C3b,  although potentiating its binding to cells,  is not a  prerequisite since 
activated P  can combine with native C3 (15, 39, 42). 
Since  incubation of cells  with  CoF-treated C3-depleted  human serum,  in 
contrast to the CoF-treated NHS, did not result in factor B fixation, and since 
isolated factor B did not bind to cells, we concluded that C3b was necessary for 
the fixation of factor B to cells.  Nicholson et al.  (44) have already shown that 
binding of factor B to zymosan particles is mediated via C3b. However, incuba- 
4  Miiller-Eberhard, H. J., O. GStze, and H. L. Spiegelberg. 1975. Activation  of the alternative 
pathway by immunoglobulin  aggregates and bacterial substances. Manuscript  in preparation. 284  PROPERDIN  AND  FACTOR  B  BINDING  TO  LYMPHOID  CELLS 
tion of soluble or cell bound C3b with factor D  and factor B  did not result in 
binding of factor B to Raji cells indicating that, apart from C3b, another serum 
factor(s) was needed for this binding. This other factor was identified as P, since 
incubation of C3b-bearing Raji cells with human serum depleted of P resulted in 
factor B fixation to cells only after reconstitution  with P.  Fearon and Austen 
have found that activated P greatly enhanced the binding of factor B to EAC43b, 
and after the addition of P with B and D to EAC43b, the hemolytic titer of either 
B or D increased 10-20-fold, and the half-life of the hemolytically active site rose 
from 4 up to 50 min (40, 41). Thus, C3b-dependent binding of P could either lead 
to more efficient interaction of factor D, factor B, and C3b or serve to stabilize 
the convertase once formed (40). After we incubated cells with zymosan-treated 
serum, from which most if not all of the P had been removed by the particles, 
factor B fixed to the cells. This fact indicates that factor B combined with large 
amounts  of C3b can fix to cells without P.  Binding of factor B  onto EAC43b 
without P  has been shown (43),  but as stated,  factor B  decays rapidly in this 
situation.  Therefore, one can envision three possible mechanisms for the bind- 
ng of C3 or C3b, P, and factor B to cells or possibly other particles: (a) activated 
P in fluid phase combines with C3, factor D, and factor B, and the whole complex 
fixes to cells' C3-C3b receptors via its C3 moiety; (b) C3b in fluid phase gener- 
ated by either the classical or alternative pathways combines with P, C3, factor 
D, and factor B and binds to C3-C3b receptors; or (c) C3 or C3b first fixes onto 
the  C3-C3b  receptor  and  thereafter  interacts  with  P,  factor D,  and  factor B. 
Since we showed that treatment of C3b-bearing Raji cells with anti-C3 abolished 
the binding of P, and others (44) showed that treatment of C3b-bearing zymosan 
particles with anti-C3 inhibited the binding of factor B to the particles, we must 
assume that both P and factor B bind directly to C3b. Thereafter the cell bound P 
+  C3 +  factor D  +  factor B or C3b +  P  +  C3 +  factor D  +  factor B complexes 
may act  upon  C3,  releasing  C3b  which  may enter  the  amplification  loop or 
positive feedback mechanism of C activation (3, 4). 
The interdependence of P  and factor B binding with the presence of C3-C3b 
receptors was obvious in several cell lines. In addition, binding of P and factor B 
complexed with C3b clearly was not mediated via the P or factor B moiety of the 
complex but through C3b, since treatment of ZC particles with anti-C3, but not 
with anti-P or antifactor B, inhibited adherence of the ZC particles to Raji cells. 
Furthermore,  addition of C3b to the Raji-ZC rosettes completely dissociated the 
rosettes and preincubation  of cells with C3b halted Raji-ZC rosette formation. 
C3d receptors do not appear to participate  in the binding of P  and factor B to 
cells since  the  MOLT-4  and  Sommer  8402  cells,  which  are  devoid of C3-C3b 
receptors but have receptors for C3d, were unable to bind these proteins. Others 
(44) have used C3b inactivator  to treat zymosan particles carrying  C3b,  thus 
releasing C3c, but leaving behind C3d (45) and have inhibited the binding of 
factor D and factor B to the particles. 
Unlike human lymphoblastoid cells, HPL incubated with NHS did not fix P. 
This result suggests that transformed cells, in contrast to HPL, acquire factors 
that can induce activation and subsequent fixation of P. However, P, as well as 
factor B, were present in approximately 25% of HPL first incubated with inulin- 
treated  human  serum.  Depletion of C3b receptor-bearing  cells from HPL re- A.  N.  THEOFILOPOULOS  AND  L.  H.  PERRIN  285 
moved the P- and factor B-fixing cells. Therefore, we concluded that the P- and 
factor B-fixing HPL were the same as the C3b receptor bearing cells which are 
considered as B type (30). This conclusion was verified when isolated C receptor 
bearing HPL were indeed found to have the capacity to bind P and factor B from 
inulin-activated human serum. 
Binding  of components of the  P  system to cells  or other  particles  may be 
important  in vivo.  It is conceivable that  the C  system is activated by trans- 
formed cells  or by other factors  following which  C3b binds  to  C3b receptor- 
bearing cells.  Cell-bound C3b may then  initiate  an  intense  utilization  of the 
terminal  components of C by formation of the factor B-dependent convertase. 
Assembly of the terminal  attack sequence of C directly on the cell membrane 
will then lead to cell lysis. This view is consistent with the following observa- 
tions: (a) factor B-dependent C3 convertase bound to erythrocytes carrying C3b 
brought the hemolytic reaction to completion with an efficiency comparable to 
that of classical C3 convertase (43),  (b) Raji cells that had absorbed C3b were 
susceptible to factor B dependent lysis (1), and a substantial percentage of 51Cr- 
labeled Raji cells incubated with NHS were lysed, ~ (c) depletion of C receptor- 
bearing  lymphocytes  from  a  mixed  lymphoid  cell  population  occurred  after 
treatment  with  CoF-activated  serum  (46),  (d)  a  parallelism  existed  between 
antitumor  effects of certain  polysaccharides and  their  ability to activate  the 
alternative  C  pathway  (47),  and  (e)  leukemia  cells  in  mice  were lysed after 
infusion of NHS, but not of heated or C5-deficient serum (48). 
The  binding  of components  of the  P  system  to  cells  might  not  only  be 
associated with lysis but might also influence other functions such as phagocyte- 
sis (49), lymphocyte proliferation and/or stimulation (50, 51), directional migra- 
tion of cells and  attraction  of other cell types (52,  53),  and responsiveness to 
external  stimuli  (52).  Studies are under ways to investigate  the influence on 
various cell activities of C3b, P, and factor B binding to C3-C3b receptor-bearing 
cells. 
Summary 
Immunofluorescence studies showed that properdin (P) and factor B bind to 
C3-C3b receptor bearing human lymphoblastoid cells (Raji, Daudi) and B type 
human peripheral lymphocytes (HPL). P bound to Raji cells first incubated with 
normal human serum (NHS). EDTA, but not EGTA, halted the binding of P to 
cells incubated with NHS. However, fixation of P  to Raji cells, after incubation 
with NHS first reacted with inulin,  was independent  of Ca ++ and Mg  ÷÷ ions. 
Fixation of P to Raji cells depended on the presence of C3 or C3b and occurred in 
the absence of factor D and factor B. Binding of P to B type HPL was detectable 
only after incubation of these cells with NHS first reacted with inulin;  under 
these conditions binding of P to Raji cells was also greatly enhanced. With both 
Raji cells and HPL, factor B was detectable on cell surfaces only after incubation 
of these cells with NHS first reacted with activators of the P system. Binding of 
factor B to cells required the presence of C3b and binding or stabilization of cell 
bound factor B  necessitated the presence of activated P.  P  and factor B  were 
s Theofilopoulos, A.  N.,  and L.  H.  Perrin.  Lysis of C3b receptor bearing human  cultured 
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detectable only on cultured cells having C3-C3b receptors. However, incubation 
of NHS with all lymphoblastoid cell lines studied resulted in activation of P  and 
cleavage of factor B. Binding of P  and factor B  to cells may follow one of three 
sequences: (a) activated P  in fluid phase combines with C3, factor D, and factor 
B, and the whole complex fixes to cellular C3-C3b receptors via its C3 moiety; (b) 
C3b generated in fluid phase combines with P,  C3,  factor D, and factor B  and 
binds to C3-C3b receptors; or (c) C3 or C3b first binds onto the C3-C3b receptors 
and thereafter interacts with P,  factor D, and factor B. 
Binding of components of the P  system to cells or other particles may relate to 
such  biological  phenomena  as  lysis,  phagocytosis,  proliferation,  attraction  of 
other cell types, and alteration of responsiveness to external stimuli. 
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